{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:15:52Z","timestamp":1790356552749,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004421","name":"Politechnika Warszawska","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004421","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012526","name":"Warsaw University of Technology Faculty of Chemistry","doi-asserted-by":"publisher","award":["NCHEM.3"],"award-info":[{"award-number":["NCHEM.3"]}],"id":[{"id":"10.13039\/501100012526","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bioorg.2024.107880","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T09:47:07Z","timestamp":1728553627000},"page":"107880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Synthesis and evaluation of anticancer activity of new 4,5,6,7-tetrabromo-1H-benzimidazole derivatives"],"prefix":"10.1016","volume":"153","author":[{"given":"Edyta","family":"\u0141ukowska-Chojnacka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egor","family":"Fedorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kowalkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Wielechowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sobiepanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miros\u0142awa","family":"Koronkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Wi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2024.107880_b0005","unstructured":"World Health Organization, Cancer 2022, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer."},{"key":"10.1016\/j.bioorg.2024.107880_b0010","doi-asserted-by":"crossref","first-page":"e1700040","DOI":"10.1002\/ardp.201700040","article-title":"Benzimidazole scaffold as anticancer agent: synthetic approaches and structure-activity relationship","volume":"350","author":"Shrivastava","year":"2017","journal-title":"Arch. Pharm. Chem. Life Sci."},{"key":"10.1016\/j.bioorg.2024.107880_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2021.213930","article-title":"First-row transition metal compounds containing bemzimidazole ligands: An overview of their anticancer and antitumor activity","volume":"439","author":"Hern\u00e1ndez-Romero","year":"2021","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.bioorg.2024.107880_b0020","doi-asserted-by":"crossref","first-page":"478e497","DOI":"10.1016\/j.apsb.2022.09.010","article-title":"Benzimidazole and its derivatives as cancer therapeutics: the potential role from traditional to precision medicine","volume":"13","author":"Lee","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2024.107880_b0025","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.2174\/1871520616666151103113412","article-title":"Prespectives of benzimidazole derivatives as anticancer agents in the new era","volume":"16","author":"Yadav","year":"2016","journal-title":"Anticancer Agents Med Chem."},{"key":"10.1016\/j.bioorg.2024.107880_b0030","first-page":"399","article-title":"Benzimidazole derivatives as potential anticancer agents","volume":"13","author":"Rashedy","year":"2013","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107880_b0035","doi-asserted-by":"crossref","first-page":"16988","DOI":"10.1038\/s41598-022-21435-6","article-title":"Quinoline-imidazole\/benzimidazole derivatives as dual-\/multi-targeting hybrids inhibitors with anticancer and antimicrobial activity","volume":"12","author":"Diaconu","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2024.107880_b0040","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.3390\/molecules24183259","article-title":"Design and synthesis of benzimidazole-chalcone derivatives as potential anticancer agent","volume":"24","author":"Hsieh","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2024.107880_b0045","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.3390\/molecules26175118","article-title":"Anticancer effect of benzimidazole derivatives, especially Mebendazole, on triple-negative breast cancer (TNBC) and radiotherapy-resistant TNBC in vivo and in vitro","volume":"26","author":"Choi","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2024.107880_b0050","doi-asserted-by":"crossref","first-page":"e2200051","DOI":"10.1002\/ardp.202200051","article-title":"Benzimidazole hybrids as anticancer drugs: A updated review on anticancer properties, structure-activity relationship, and mechanisms of action","volume":"355","author":"Feng","year":"2022","journal-title":"Arch. Phar"},{"key":"10.1016\/j.bioorg.2024.107880_b0055","first-page":"519","article-title":"Novel benzimidazole derivatives as expected anticancer agents","volume":"68","author":"Nofal","year":"2011","journal-title":"Acta Pol. Pharm Drug Res."},{"key":"10.1016\/j.bioorg.2024.107880_b0060","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1080\/14786419.2017.1389940","article-title":"Design, synthesis and biological evaluation of chrysin benzimidazole derivatives as potential anticancer agents","volume":"32","author":"Wanga","year":"2018","journal-title":"Nat. Prod. Res."},{"key":"10.1016\/j.bioorg.2024.107880_b0065","doi-asserted-by":"crossref","unstructured":"K. Ahmed, A.T. Davis, H. Wang, R.A. Faust, S. Yu, S. J. Tawfic, Significance of protein kinase CK2 nuclear signaling in neoplasia. Cell. Biochem. Suppl. 2000, supll 35, 130-135. https:\/\/doi.org\/10.1002\/1097-4644(2000)79:35+<130::AID-JCB1136>3.0.CO;2-N.","DOI":"10.1002\/1097-4644(2000)79:35+<130::AID-JCB1136>3.0.CO;2-N"},{"key":"10.1016\/j.bioorg.2024.107880_b0070","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1007\/s00018-009-9154-y","article-title":"CK2, A key player in cancer biology","volume":"66","author":"Trembley","year":"2009","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.bioorg.2024.107880_b0075","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11010-008-9827-0","article-title":"New inhibitors of protein kinase CK2, analogues of benzimidazole and benzotriazole","volume":"316","author":"Bretner","year":"2008","journal-title":"Mol. Cell Biochem."},{"key":"10.1016\/j.bioorg.2024.107880_b0080","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0014-5793(01)02404-8","article-title":"Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2')","volume":"496","author":"Sarno","year":"2001","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bioorg.2024.107880_b0085","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1021\/jm049854a","article-title":"Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole","volume":"47","author":"Pagano","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107880_b0090","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1016\/j.bmc.2009.08.047","article-title":"Tetraiodobenzimidazoles are potent inhibitors of protein kinase CK2","volume":"17","author":"Gianoncelli","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107880_b0095","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1016\/j.bmc.2012.05.038","article-title":"Modified tetrahalogenated benzimidazoles with CK2 inhibitory activity are active against human prostate cancer cells LNCaP in vitro","volume":"20","author":"Schneider","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107880_b0100","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.bbapap.2005.07.039","article-title":"Tetrabromobenzotriazole (TBBt) and tetrabromobenzimidazole (TBBz) as selective inhibitors of protein kinase CK2: evaluation of their effects on cells and different molecular forms of human CK2","volume":"1754","author":"Zie\u0144","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bioorg.2024.107880_b0105","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/sj.leu.2404460","article-title":"Treatment of P190 Bcr\/Abl lymphoblastic leukemia cells with inhibitors of the serine\/threonine kinase CK2","volume":"21","author":"Mishra","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2024.107880_b0110","first-page":"635","article-title":"Synthesis and proapoptotic properties of new casein kinase II inhibitors","volume":"67","author":"Koronkiewicz","year":"2010","journal-title":"Acta Pol. Pharm."},{"key":"10.1016\/j.bioorg.2024.107880_b0115","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3892\/ijo_00000424","article-title":"Efficacy and mechanism of anti-tumor action of new potential CK2 inhibitors toward glioblastoma cells","volume":"35","author":"Kami\u0144ska","year":"2009","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bioorg.2024.107880_b0120","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.canlet.2007.06.010","article-title":"Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT","volume":"256","author":"Yde","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2024.107880_b0125","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1007\/s00018-013-1552-5","article-title":"Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential","volume":"71","author":"Cozza","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bioorg.2024.107880_b0130","doi-asserted-by":"crossref","unstructured":"M. Koronkiewicz, Z. Kazimierczuk, A. Orzeszko. BMC Cancer Antitumor activity of the protein kinase inhibitor 1-(\u03b2-D-2-deoxyribofuranosyl)-4,5,6,7-tetrabromo-1H-benzimidazole in breast cancer cell lines. 2022, 22, 1069, https:\/\/doi.org\/10.1186\/s12885-022-10156-8.","DOI":"10.1186\/s12885-022-10156-8"},{"key":"10.1016\/j.bioorg.2024.107880_b0135","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bioorg.2018.06.022","article-title":"Biological properties and structural study of new aminoalkyl derivatives of benzimidazole and benzotriazole, dual inhibitors of CK2 and PIM1 kinases","volume":"80","author":"Chojnacki","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107880_b0140","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.3390\/ijms22126261","article-title":"Synthesis of novel acyl derivatives of 3-(4,5,6,7-tetrabromo-1H-benzimidazol-1-yl)propan-1-ols - intracellular TBBi-based CK2 inhibitors with proapoptotic properties","volume":"22","author":"Chojnacki","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107880_b0145","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.3390\/pharmaceutics15071991","article-title":"Synthesis and anticancer activity of novel dual inhibitors of human protein kinases CK2 and PIM-1","volume":"15","author":"Wi\u0144ska","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2024.107880_b0150","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.tox.2008.07.048","article-title":"Cell death and autophagy: cytokines, drugs, and nutritional factors","volume":"254","author":"Bursch","year":"2008","journal-title":"Toxicology"},{"key":"10.1016\/j.bioorg.2024.107880_b0155","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/cancers16050984","article-title":"Impact of complex apoptotic signaling pathways on cancer cell sensitivity to therapy","volume":"16","author":"Kim","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2024.107880_b0160","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10549-008-0217-9","article-title":"MCF-7 breast carcinoma cells do not express caspase-3","volume":"117","author":"J\u00e4nicke","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bioorg.2024.107880_b0165","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41416-021-01616-2","article-title":"CSNK2 in cancer: pathophysiology and translational applications","volume":"126","author":"Strum","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2024.107880_b0170","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","article-title":"UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses","volume":"19","author":"Chandrashekar","year":"2017","journal-title":"Neoplasia"},{"key":"10.1016\/j.bioorg.2024.107880_b0175","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11010-016-2765-3","article-title":"Examination of CK2\u03b1 and NF-\u03baB p65 expression in human benign prostatic hyperplasia and prostate cancer tissues","volume":"420","author":"Qaiser","year":"2016","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bioorg.2024.107880_b0180","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11010-005-3078-0","article-title":"CK2 as a positive regulator of Wnt signalling and tumourigenesis","volume":"274","author":"Seldin","year":"2005","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bioorg.2024.107880_b0185","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1158\/1535-7163.MCT-15-0943","article-title":"High expression of miR-532-5p, a tumor suppressor, leads to better prognosis in ovarian cancer both in vivo and in vitro","volume":"15","author":"Wang","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2024.107880_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/leu.2017.301","article-title":"Therapeutic targeting of CK2 in acute and chronic leukemias","volume":"32","author":"Buontempo","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2024.107880_b0195","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1074\/jbc.M006115200","article-title":"Nuclear factor-\u03baB activation by the CXC chemokine melanoma growth-stimulatory activity\/growth-regulated protein involves the MEKK1\/p38 mitogen-activated protein kinase pathway","volume":"276","author":"Wang","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2024.107880_b0200","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11010-011-0956-5","article-title":"Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer","volume":"356","author":"Pierre","year":"2011","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bioorg.2024.107880_b0205","doi-asserted-by":"crossref","first-page":"11352","DOI":"10.1074\/jbc.M109062200","article-title":"AKT\/PKB phosphorylation of p21Cip\/WAF1 enhances protein stability of p21Cip\/WAF1 and promotes cell survival","volume":"277","author":"Yi","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2024.107880_b0210","doi-asserted-by":"crossref","first-page":"10288","DOI":"10.1158\/0008-5472.CAN-10-1893","article-title":"CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy","volume":"70","author":"Siddiqui-Jain","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2024.107880_b0215","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejmech.2014.07.019","article-title":"Synthesis of novel chiral TBBt derivatives with hydroxyl moiety. Studies on inhibition of human protein kinase CK2\u03b1 and cytotoxicity properties","volume":"84","author":"Borowiecki","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107880_b0220","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.bioorg.2024.107880_b0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bioorg.2017.02.017","article-title":"Synthesis, in vitro antiproliferative activity and kinase profile of new benzimidazole and benzotriazole derivatives","volume":"72","author":"Chojnacki","year":"2017","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107880_b0230","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824007855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824007855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T02:25:44Z","timestamp":1738203944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824007855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":46,"alternative-id":["S0045206824007855"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107880","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and evaluation of anticancer activity of new 4,5,6,7-tetrabromo-1H-benzimidazole derivatives","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107880","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107880"}}